Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.52 |
| ▸ | APEX1 | P27695 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | BBOX1 | O75936 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2936558 | 0.96 | ACHE (0.52) | ACHEAPEX1NPSR1BBOX1MAPT | |
| Methacrylic Acid SCHEMBL6561454 | 0.94 | ACHE (0.52) | ACHEAPEX1NPSR1BBOX1MAPT | |
| Hydrochloric Acid SCHEMBL8222907 | 0.92 | ACHE (0.45) | ACHEAPEX1NPSR1BBOX1MAPT | |
| Hydrochloric Acid SCHEMBL8695365 | 0.92 | ACHE (0.45) | ACHEAPEX1NPSR1BBOX1MAPT | |
| Hydrochloric Acid SCHEMBL9497105 | 0.92 | APEX1 (0.48) | ACHEAPEX1NPSR1ENPP2TBXAS1 | |
| Hydrochloric Acid SCHEMBL1703796 | 0.89 | ACHE (0.45) | ACHEAPEX1NPSR1BBOX1ENPP2 | |
| Methacrylic Acid SCHEMBL159154 | 0.87 | ACHE (0.48) | ACHEBBOX1ENPP2SMN1; SMN2ADRA2A | |
| Hydrochloric Acid SCHEMBL6550800 | 0.86 | BLM (0.41) | ACHEAPEX1MAPTBLMENPP2 | |
| Hydrochloric Acid SCHEMBL7209013 | 0.85 | ACHE (0.39) | ACHEBBOX1MAPTBLMENPP2 | |
| SCHEMBL7093817 | 0.84 | ACHE (0.41) | ACHEAPEX1MAPTBLMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358333-B1 | COATED COLORING AGENTS | HENKEL AG & CO KGAA (DE) | 2016-08-17 | — | — | EP | claimed |
| US-9308176-B2 | Less abusable pharmaceutical preparations | SUPERNUS PHARMACEUTICALS, INC (US) | 2016-04-12 | — | — | US | claimed |
| US-9144551-B2 | Drug formulations having reduced abuse potential | SUPERNUS PHARMACEUTICALS, INC. (US) | 2015-09-29 | — | — | US | claimed |
| US-20150150816-A1 | DRUG FORMULATIONS HAVING REDUCED ABUSE POTENTIAL | SUPERNUS PHARMACEUTICALS, INC. (US) | 2015-06-04 | — | — | US | claimed |
| US-8906413-B2 | Drug formulations having reduced abuse potential | SUPERNUS PHARMACEUTICALS, INC. (US) | 2014-12-09 | — | — | US | claimed |
| EP-1809259-B1 | LESS ABUSABLE PHARMACEUTICAL PREPARATIONS | SUPERNUS PHARMACEUTICALS INC (US) | 2014-12-03 | — | — | EP | claimed |
| EP-1624860-B1 | DRUG FORMULATIONS HAVING REDUCED ABUSE POTENTIAL | SUPERNUS PHARMACEUTICALS INC (US) | 2014-02-12 | — | — | EP | claimed |
| EP-2494961-A1 | Drug formulations having reduced abuse potential | Supernus Pharmaceuticals, Inc. (US) | 2012-09-05 | — | — | EP | claimed |
| US-20100029853-A1 | Controlled architecture copolymers prepared from vinyl phosphonate monomers | Rhodia Receherches et Technologies (FR) | 2010-02-04 | — | — | US | claimed |
| US-20090306297-A1 | PROCESS FOR PREPARING A COPOLYMER WITH CONTROLLED ARCHITECTURE, OF TELOMER OR BLOCK COPOLYMER TYPE, OBTAINED FROM VINYL PHOSPHONATE MONOMERS, BY IODINE TRANSFER POLYMERIZATION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-12-10 | — | — | US | claimed |
| WO-2006044805-A2 | LESS ABUSABLE PHARMACEUTICAL PREPARATIONS | SUPERNUS PHARMACEUTICALS, INC. (US) | 2006-04-27 | — | — | WO | claimed |
| US-20060083690-A1 | Less abusable pharmaceutical preparations | SUPERNUS PHARMACEUTICALS, INC. | 2006-04-20 | — | — | US | claimed |
| EP-1624860-A2 | DRUG FORMULATIONS HAVING REDUCED ABUSE POTENTIAL | Shire Laboratories Inc. (US) | 2006-02-15 | — | — | EP | claimed |
| US-6974591-B2 | Method for producing a controlled-release preparation | WATSON LABORATORIES, INC. (US) | 2005-12-13 | — | — | US | claimed |
| WO-2004100894-A2 | DRUG FORMULATIONS HAVING REDUCED ABUSE POTENTIAL | SHIRE LABORATORIES, INC. (US) | 2004-11-25 | — | — | WO | claimed |
| EP-1478349-A1 | A METHOD FOR RELEASING NANOSIZED PARTICLES OF AN ACTIVE SUBSTANCE FROM A DIFFUSION-CONTROLLED PHARMACEUTICAL COMPOSITION FOR ORAL USE | Amarin Development AB (SE) | 2004-11-24 | — | — | EP | claimed |
| US-20040228802-A1 | Dosage forms when the drug is properly administered, free of bitter taste, no coloring; when administering not follow the instructions, crushed or extracted and nasally, orally, buccally or sublingually administered, drug will taste bitter, forming color to stain human tissue | SUPERNUS PHARMACEUTICALS, INC. | 2004-11-18 | — | — | US | claimed |
| US-20030215513-A1 | Method for releasing nanosized particles of an active substance from a diffusion-controlled pharmaceutical composition for oral use | AMARIN DEVELOPMENT AB (SE) | 2003-11-20 | — | — | US | claimed |
| WO-2003070225-A1 | A METHOD FOR RELEASING NANOSIZED PARTICLES OF AN ACTIVE SUBSTANCE FROM A DIFFUSION-CONTROLLED PHARMACEUTICAL COMPOSITION FOR ORAL USE | AMARIN DEVELOPMENT AB (SE) | 2003-08-28 | — | — | WO | claimed |
| US-4758437-A | Composition for long acting nicardipine preparation and process of producing the composition | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1988-07-19 | — | — | US | claimed |